Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16391138 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HPGDMAPTGAALMNA | |
| SCHEMBL16698452 | 1.00 | ALDH1A1 (0.48) | ALDH1A1HPGDMAPTGAALMNA | |
| SCHEMBL28564290 | 0.90 | ALDH1A1 (0.44) | ALDH1A1HPGDMAPTGAALMNA | |
| SCHEMBL16698519 | 0.83 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL16391136 | 0.83 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL16370671 | 0.83 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL19024529 | 0.82 | AR (0.45) | ALDH1A1MAPTGAAARMAPK1 | |
| SCHEMBL16698134 | 0.81 | CASP6 (0.44) | — | |
| SCHEMBL16391135 | 0.81 | CASP6 (0.44) | — | |
| SCHEMBL16698136 | 0.81 | CASP6 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486865-A | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-112592334-B | Pyrimidine derivatives as kinase inhibitors | 艾森医药公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20210309642-A1 | Process for Manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and Formulations Thereof | ACEA Therapeutics, Inc. (US) | 2021-10-07 | — | — | US | disclosed |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | ACEA Therapeutics, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2020029156-A1 | PROCESS FOR MANUFACTURE OF (S)-N-(3-((2-((4-((1-ACETYLPYRROLIDIN-3-YL)(METHYL)AMINO)PHENYL)AMINO)-5-METHOXYPYRIMIDIN-4-YL)OXY) PHENYL)ACRYLAMIDE, AND FORMULATIONS THEREOF | ACEA Therapeutics, Inc. (US) | 2020-02-13 | — | — | WO | disclosed |
| EP-3019496-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ACEA THERAPEUTICS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20180251475-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2018-09-06 | — | — | US | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920074-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-9464089-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464089-B2 | Heterocyclic compounds and uses thereof | ACEA BIOSCIENCES INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA BIOSCIENCES INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029442-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | ALDH1A1 4165/4885HPGD 2451/4885MAPT 2803/4885 |
| US-20150133457-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | ALDH1A1 4165/4885HPGD 2451/4885MAPT 2803/4885 |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | BMX, BLK, BTK | ALDH1A1 4165/4885HPGD 2451/4885MAPT 2803/4885 |
| US-20210309642-A1 | Process for Manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and Formulations Thereof | BMX, ITK, BLK | ALDH1A1 3882/4885HPGD 4121/4885MAPT 2914/4885 |
| US-20180251475-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BMX, BLK, BTK | ALDH1A1 4165/4885HPGD 2451/4885MAPT 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.